- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT02788058
A Study of Hypofractionated Radiotherapy for Limited Metastatic NSCLC Harboring Sensitizing EGFR Mutations After First Line TKI Therapy
A Phase II Trial of Hypofractionated Radiotherapy for Limited Metastatic NSCLC Harboring Sensitizing EGFR Mutations After First Line TKI Therapy
Studieöversikt
Status
Intervention / Behandling
Detaljerad beskrivning
Rational:
After inductive TKI therapy in NSCLC with sensitizing EGFR mutations, the residual lesion might be the source of subsequent disease progression, defined as acquired resistance to TKI. Two reasons can be used to explain the formation of the residual lesion:1)there is a subgroup of cancer cells that are not sensitive to TKI therapy because of tumor heterogeneity, like de novo T790M mutation; 2)some cancer cells can keep static state during the beginning treatment, and then develops acquired resistance to TKI therapy under the long-term drug pressure and continue to re-proliferation. From this point of view, elimination of residual lesion provides the chance to reduce or slow the possibility of developing resistance to TKI.
Objective:
To evaluate the efficacy and toxicity of patients treated with hypofractionated radiotherapy for limited metastatic NSCLC harboring sensitizing EGFR mutations after first line TKI therapy. An exploratory biomarker analysis in blood and tumor samples is also planned.
Studietyp
Inskrivning (Förväntat)
Fas
- Fas 2
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- Newly diagnosed metastatic lung adenocarcinoma harboring sensitizing EGFR mutations (L858R, exon 19 deletion), and became oligometastatic disease after 3 months TKI, evaluated by PET/CT scan, brain MRI, and abdomen ultrasound (≤6 discrete lesions of disease, exclusive of the brain metastases, ≤3 lesions in the liver, ≤3 lesions in the lung);
- All sites of disease must be amenable to definitive RT;
- An intrathoracic lymph nodal station is considered 1 discrete lesion, according to IASLC lymph nodal station map;
- Age 18 years or older;
- ECOG Performance Status 0-2;
- Adequate bone marrow, liver and renal function, as specified below: Absolute Neutrophil Count (ANC) ≥ 1.5 x 109/L; Hemoglobin ≥ 8 g/dL; Platelets ≥ 100 x 109/L; Serum total bilirubin ≤ 1.5 x upper limit of normal (ULN) ; AST and ALT ≤ 2.5 x ULN or ≤ 5 x ULN if liver metastases are present; Serum creatinine ≤ 1.5 x upper limit of normal or creatinine clearance ≥ 60ml/min for patients with creatinine levels above institutional normal;
- For women of child-bearing potential, negative pregnancy test within 14 days prior to starting treatment;
- Men and women of childbearing age must be willing to use effective contraception while on treatment and for at least 3 months thereafter;
- Patients and their family signed the informed consents;
Exclusion Criteria:
- Received chemotherapy before TKI therapy;
- Brain parenchyma or leptomeningeal disease;
- Any site of disease that is not amenable to definitive RT;
- Concurrent malignancies other than non-melanoma skin cancer that require active ongoing treatment;
- Any medical co-morbidities that would preclude radiation therapy.
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
---|---|
Experimentell: EGFR-TKI
Patients take EGFR-TKI alone till tumor progression
|
Gefitinib 250mg po qd or Erlotinib 150mg po qd or Icotinib 125mg po tid
Andra namn:
|
Aktiv komparator: EGFR-TKI+hypofractionated radiotherapy
After 3 mos TKI, patients with limited metastatic take EGFR-TKI concurrent with hypofractionated radiotherapy till tumor progression.
|
40-45 Gy/5-15f
Gefitinib 250mg po qd or Erlotinib 150mg po qd or Icotinib 125mg po tid
Andra namn:
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Tidsram |
---|---|
Progressionsfri överlevnad
Tidsram: 3 år
|
3 år
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Att bedöma den kortsiktiga livskvaliteten (QOL)
Tidsram: 4 månader
|
FACT-E-poäng vid 4 månader efter konsolideringsterapi med docetaxel
|
4 månader
|
Frequency of T790M mutation before treatment detected by ctDNA
Tidsram: 1 months
|
1 months
|
|
Abundance of T790M mutation before treatment detected by ctDNA
Tidsram: 1 months
|
1 months
|
|
Frequency of T790M mutation after radiotherapy detected by ctDNA
Tidsram: 3 months
|
3 months
|
|
Abundance of T790M mutation after radiotherapy detected by ctDNA
Tidsram: 3 months
|
3 months
|
|
Frequency of T790M mutation after 1 year detected by ctDNA
Tidsram: 1 year
|
1 year
|
|
Abundance of T790M mutation after 1 year detected by ctDNA
Tidsram: 1 year
|
1 year
|
|
Rate of CTCAE grade 2 or higher radiation pneumonitis
Tidsram: 1 years
|
We will assess the rate of symptomatic radiation pneumonitis in patients who received the radiation therapy.
|
1 years
|
Samarbetspartners och utredare
Studieavstämningsdatum
Studera stora datum
Studiestart
Primärt slutförande (Förväntat)
Avslutad studie (Förväntat)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Uppskatta)
Uppdateringar av studier
Senaste uppdatering publicerad (Uppskatta)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
- Neoplasmer efter histologisk typ
- Neoplasmer
- Neoplasmer efter plats
- Carcinom
- Neoplasmer, körtel och epitel
- Neoplasmer i andningsvägarna
- Thoracic neoplasmer
- Lungneoplasmer
- Adenocarcinom
- Adenocarcinom i lungan
- Molekylära mekanismer för farmakologisk verkan
- Enzyminhibitorer
- Antineoplastiska medel
- Proteinkinashämmare
- Gefitinib
Andra studie-ID-nummer
- HZCH-2016-08
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Lungadenokarcinom
-
Imugene LimitedAktiv, inte rekryterandeIcke småcellig lungcancer | Icke småcellig lungcancer Stadium IIIB | Icke-småcellig lungcancer Steg IV | Skivepitelcancer, icke-småcellig lungcancer | Storcellscancer Lung | Adenocarcinom LungFörenta staterna, Australien
-
Maastricht UniversityRadboud University Medical Center; University of California, San FranciscoOkändIcke småcellig lungcancerNederländerna
-
National Cancer Institute (NCI)AvslutadSteg IIIA Icke-småcellig lungcancer AJCC v7 | Steg IIIB Icke-småcellig lungcancer AJCC v7 | Steg IV, icke-småcellig lungcancer AJCC v7 | Steg III, icke-småcellig lungcancer AJCC v7 | Lokalt avancerad lung-icke-skivepitelcancer, icke-småcellig karcinom | Steg III lungadenokarcinom AJCC v7 | Steg III... och andra villkorFörenta staterna
-
RenJi HospitalRekryteringLungcancer | Icke småcellig lungcancer | Lungadenokarcinom | Lung skivepitelcancerKina
-
Chang Gung Memorial HospitalAvslutad
-
Xuzhou Central HospitalAvslutadLungcancer, Adenocarcinom | Lunginflammatorisk pseudotumorKina
-
University of ZurichDeep Breath Intelligence (DBI)RekryteringLung-/luftvägssjukdomarSchweiz
-
424 General Military HospitalAvslutad
-
Celularity IncorporatedAvslutadSteg 2 Lung sarkoidos | Steg 3 Lung sarkoidosFörenta staterna
-
Azienda Sanitaria-Universitaria Integrata di UdineRekryteringLungsjukdomar | Lungcancer | Lungadenokarcinom | Avstötning av lungtransplantation | Lunga; Nod | Lung-TBItalien
Kliniska prövningar på Thorax hypofraktionerad strålbehandling
-
Institut Català d'OncologiaRekrytering
-
Institut für Klinische Krebsforschung IKF GmbH...AstraZeneca; Thoraxklinik-Heidelberg gGmbHRekrytering
-
Fundacao ChampalimaudOkänd
-
Memorial Sloan Kettering Cancer CenterAktiv, inte rekryterandeMetastaserande cancerFörenta staterna
-
M.D. Anderson Cancer CenterAvslutadIcke-småcellig lungcancerFörenta staterna
-
Arizona Heart InstituteOkändSjunkande Thoracic Aorta SjukdomFörenta staterna
-
Cancer Trials IrelandUniversity College Dublin; Technological University DublinRekryteringNSCLC/Oligometastatisk cancer (enkel lungskada)Irland
-
W.L.Gore & AssociatesAvslutadAortaaneurysm, thoraxFörenta staterna
-
Université du Québec à Trois-RivièresOkänd
-
Bolton MedicalAktiv, inte rekryterandeAnnan specificerad skada på Thoracic AortaFörenta staterna